Structure-Based Discovery of Negative Allosteric Modulators of the Metabotropic Glutamate Receptor 5. 2022

Stefanie Kampen, and David Rodríguez, and Morten Jørgensen, and Monika Kruszyk-Kujawa, and Xinyan Huang, and Michael Collins, and Noel Boyle, and Damien Maurel, and Axel Rudling, and Guillaume Lebon, and Jens Carlsson
Science for Life Laboratory, Department of Cell and Molecular Biology, Uppsala University, SE-751 24 Uppsala, Sweden.

Recently determined structures of class C G protein-coupled receptors (GPCRs) revealed the location of allosteric binding sites and opened new opportunities for the discovery of novel modulators. In this work, molecular docking screens for allosteric modulators targeting the metabotropic glutamate receptor 5 (mGlu5) were performed. The mGlu5 receptor is activated by the main excitatory neurotransmitter of the nervous central system, L-glutamate, and mGlu5 receptor activity can be allosterically modulated by negative or positive allosteric modulators. The mGlu5 receptor is a promising target for the treatment of psychiatric and neurodegenerative diseases, and several allosteric modulators of this GPCR have been evaluated in clinical trials. Chemical libraries containing fragment- (1.6 million molecules) and lead-like (4.6 million molecules) compounds were docked to an allosteric binding site of mGlu5 identified in X-ray crystal structures. Among the top-ranked compounds, 59 fragments and 59 lead-like compounds were selected for experimental evaluation. Of these, four fragment- and seven lead-like compounds were confirmed to bind to the allosteric site with affinities ranging from 0.43 to 8.6 μM, corresponding to a hit rate of 9%. The four compounds with the highest affinities were demonstrated to be negative allosteric modulators of mGlu5 signaling in functional assays. The results demonstrate that virtual screens of fragment- and lead-like chemical libraries have complementary advantages and illustrate how access to high-resolution structures of GPCRs in complex with allosteric modulators can accelerate lead discovery.

UI MeSH Term Description Entries
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D000494 Allosteric Regulation The modification of the reactivity of ENZYMES by the binding of effectors to sites (ALLOSTERIC SITES) on the enzymes other than the substrate BINDING SITES. Regulation, Allosteric,Allosteric Regulations,Regulations, Allosteric
D000495 Allosteric Site A site on an enzyme which upon binding of a modulator, causes the enzyme to undergo a conformational change that may alter its catalytic or binding properties. Allosteric Sites,Site, Allosteric,Sites, Allosteric
D043562 Receptors, G-Protein-Coupled The largest family of cell surface receptors involved in SIGNAL TRANSDUCTION. They share a common structure and signal through HETEROTRIMERIC G-PROTEINS. G Protein Coupled Receptor,G-Protein-Coupled Receptor,G-Protein-Coupled Receptors,G Protein Coupled Receptors,Receptor, G-Protein-Coupled,Receptors, G Protein Coupled
D054852 Small Molecule Libraries Large collections of small molecules (molecular weight about 600 or less), of similar or diverse nature which are used for high-throughput screening analysis of the gene function, protein interaction, cellular processing, biochemical pathways, or other chemical interactions. It includes virtual libraries. Chemical Libraries,Molecular Libraries, Small,Libraries, Chemical,Libraries, Small Molecular,Libraries, Small Molecule,Molecule Libraries, Small,Small Molecular Libraries
D062105 Molecular Docking Simulation A computer simulation technique that is used to model the interaction between two molecules. Typically the docking simulation measures the interactions of a small molecule or ligand with a part of a larger molecule such as a protein. Molecular Docking,Molecular Docking Simulations,Molecular Docking Analysis,Analysis, Molecular Docking,Docking Analysis, Molecular,Docking Simulation, Molecular,Docking, Molecular,Molecular Docking Analyses,Molecular Dockings,Simulation, Molecular Docking
D018698 Glutamic Acid A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM. Aluminum L-Glutamate,Glutamate,Potassium Glutamate,D-Glutamate,Glutamic Acid, (D)-Isomer,L-Glutamate,L-Glutamic Acid,Aluminum L Glutamate,D Glutamate,Glutamate, Potassium,L Glutamate,L Glutamic Acid,L-Glutamate, Aluminum
D064529 Receptor, Metabotropic Glutamate 5 A type I G protein-coupled receptor mostly expressed post-synaptic pyramidal cells of the cortex and CENTRAL NERVOUS SYSTEM. Metabotropic Glutamate Receptor 5,Receptor 5, Metabotropic Glutamate,Metabotropic Glutamate Receptor 5a,Metabotropic Glutamate Receptor 5b,mGluR5 Protein,mGluR5a Protein,mGluR5b Protein,Protein, mGluR5,Protein, mGluR5a,Protein, mGluR5b

Related Publications

Stefanie Kampen, and David Rodríguez, and Morten Jørgensen, and Monika Kruszyk-Kujawa, and Xinyan Huang, and Michael Collins, and Noel Boyle, and Damien Maurel, and Axel Rudling, and Guillaume Lebon, and Jens Carlsson
January 2020, Advances in pharmacology (San Diego, Calif.),
Stefanie Kampen, and David Rodríguez, and Morten Jørgensen, and Monika Kruszyk-Kujawa, and Xinyan Huang, and Michael Collins, and Noel Boyle, and Damien Maurel, and Axel Rudling, and Guillaume Lebon, and Jens Carlsson
January 2019, Bioorganic & medicinal chemistry letters,
Stefanie Kampen, and David Rodríguez, and Morten Jørgensen, and Monika Kruszyk-Kujawa, and Xinyan Huang, and Michael Collins, and Noel Boyle, and Damien Maurel, and Axel Rudling, and Guillaume Lebon, and Jens Carlsson
June 2013, ACS medicinal chemistry letters,
Stefanie Kampen, and David Rodríguez, and Morten Jørgensen, and Monika Kruszyk-Kujawa, and Xinyan Huang, and Michael Collins, and Noel Boyle, and Damien Maurel, and Axel Rudling, and Guillaume Lebon, and Jens Carlsson
January 2005, Current topics in medicinal chemistry,
Stefanie Kampen, and David Rodríguez, and Morten Jørgensen, and Monika Kruszyk-Kujawa, and Xinyan Huang, and Michael Collins, and Noel Boyle, and Damien Maurel, and Axel Rudling, and Guillaume Lebon, and Jens Carlsson
March 2011, Bioorganic & medicinal chemistry letters,
Stefanie Kampen, and David Rodríguez, and Morten Jørgensen, and Monika Kruszyk-Kujawa, and Xinyan Huang, and Michael Collins, and Noel Boyle, and Damien Maurel, and Axel Rudling, and Guillaume Lebon, and Jens Carlsson
June 2018, Bioorganic & medicinal chemistry letters,
Stefanie Kampen, and David Rodríguez, and Morten Jørgensen, and Monika Kruszyk-Kujawa, and Xinyan Huang, and Michael Collins, and Noel Boyle, and Damien Maurel, and Axel Rudling, and Guillaume Lebon, and Jens Carlsson
July 2016, ACS chemical biology,
Stefanie Kampen, and David Rodríguez, and Morten Jørgensen, and Monika Kruszyk-Kujawa, and Xinyan Huang, and Michael Collins, and Noel Boyle, and Damien Maurel, and Axel Rudling, and Guillaume Lebon, and Jens Carlsson
July 2017, Cell chemical biology,
Stefanie Kampen, and David Rodríguez, and Morten Jørgensen, and Monika Kruszyk-Kujawa, and Xinyan Huang, and Michael Collins, and Noel Boyle, and Damien Maurel, and Axel Rudling, and Guillaume Lebon, and Jens Carlsson
August 2013, Bioorganic & medicinal chemistry letters,
Stefanie Kampen, and David Rodríguez, and Morten Jørgensen, and Monika Kruszyk-Kujawa, and Xinyan Huang, and Michael Collins, and Noel Boyle, and Damien Maurel, and Axel Rudling, and Guillaume Lebon, and Jens Carlsson
July 2012, ACS medicinal chemistry letters,
Copied contents to your clipboard!